You are here
Roy Fleischmann, MD
Dr Fleischmann is a Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and in private practice at Rheumatology Associates Dallas, Texas. He has served as Chief of the Division of Rheumatology at UTSMC-University Hospitals-St. Paul in Dallas since 1978. Dr Fleishmann is the Co-Medical Director of Metroplex Clinical Research Center.
He received his Doctorate of Medicine from the State University of New York, Downstate Medical Center in 1969 before completing his residency in Internal Medicine at Mount Sinai Hospital in New York City. He completed his fellowship in rheumatology at the College of Physicians and Surgeons at Columbia University in New York City.
He is a Diplomat of the American Board of Internal Medicine and a Fellow of the American College of Rheumatology. He has served on the Finance Committee of the American College of Rheumatology and the Fundraising Committee of the Research and Education Foundation of the American College of Rheumatology. He has previously served on the Board of Directors and the Executive Committee of the North Texas Chapter of the Arthritis Foundation. He has been President of the Texas Rheumatism Society and has sat on the governing board of the Texas Rheumatism Association. Dr Fleischmann is an internationally recognized thought leader in the education of other rheumatologists and in the development of new medications for the treatment of patients with various forms of arthritis. He has been a consultant in clinical trial design, protocol development, and Continuing Medical Education activities. He is a member of the Inflammation Research Association, the Associates of Clinical Pharmacology, and the Drug Information Association. He has been involved in many clinical trials on treatments for osteoarthritis and rheumatoid arthritis and has published over 60 peer-reviewed articles in these areas. Dr Fleischmann has been voted one of the “Best Doctors in Dallas” as well as a “Texas Super Doctor.”
Consultant/Advisor: Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, UCB, Inc.
Grant/Research Support: Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, UCB, Inc.
Speakers’ Bureau: Pfizer Inc.